August 23, 2024 06:45 AM EDTUpdated 07:23 AM
Startups
Cell/Gene Tx

Gene in­ser­tion start­up Tome Bio­sciences stops lab work as CEO shifts fo­cus to deal talks

Ryan Cross

Senior Science Correspondent

Tome Bio­sciences, a high-pro­file gene edit­ing start­up spun out of MIT, is halt­ing its lab work and look­ing to sell it­self or find a part­ner …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Seres' mi­cro­bio­me ther­a­py re­duces in­fec­tions in stem cell trans­plant pa­tients, but next steps are un­clear

Mod­er­na plans $1.1B in R&D and pro­gram cuts, de­lays break-even point to 2028

Charles Riv­er to lay off 3% of staffers as it stream­lines spend­ing

Sofinno­va’s Jim Healy on ‘more ra­tio­nal mar­ket’ as four biotech star­tups near their IPOs

Noom of­fers com­pound­ed GLP-1 drugs, promis­es pa­tients can quit and keep weight off

FDA should em­brace new ways of eval­u­at­ing rare dis­ease drugs, re­port ar­gues

A service from the Financial Times